Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC

Clinical Chemistry

Volumn 55, Issue 12, 2009, Pages 2180-2189

  Schwilke, Eugene W ^a   Schwope, David M ^a   Karschner, Erin L ^a   Lowe, Ross H ^a   Darwin, William D ^a   Kelly, Deanna L ^b   Goodwin, Robert S ^a   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYDRONABINOL; BETA GLUCURONIDASE; DRONABINOL; TETRAHYDROCANNABINOLIC ACID; 11 HYDROXY DELTA(9) TETRAHYDROCANNABINOL; 11 NOR DELTA(9) TETRAHYDROCANNABINOL 9 CARBOXYLIC ACID; 11-HYDROXY-DELTA(9)-TETRAHYDROCANNABINOL; 11-NOR-DELTA(9)-TETRAHYDROCANNABINOL-9-CARBOXYLIC ACID; DRUG DERIVATIVE; TETRAHYDROCANNABINOL;

ADULT; ARTICLE; CANNABIS SMOKING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; ESCHERICHIA COLI; HUMAN; HYDROLYSIS; MALE; MASS FRAGMENTOGRAPHY; QUANTITATIVE ANALYSIS; ADOLESCENT; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

CANNABIS; ESCHERICHIA COLI;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ESCHERICHIA COLI; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCURONIDASE; HUMANS; HYDROLYSIS; MALE; MIDDLE AGED; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 71749110966     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.122119     Document Type: Article

References (39)

1. Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 2007;20: 393-397 (Pubitemid 46889667)
2. Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Invest Drugs 2008;9:65-75.
3. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008;197:157-168
4. Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict 2008;17:161-164
5. Walsh JM, de Gier JJ, Christopherson AS, Verstraete AG. Drugs and driving. Traffic Inj Prev 2004;5:241-253
6. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 2006;85: 114-122 (Pubitemid 44468137)
7. Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, Swann P. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004;36:239-248
8. Menetrey A, Augsburger M, Favrat B, Pin MA, Rothuizen LE, Appenzeller M, et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg delta9-THC. J Anal Toxicol 2005;29:327-338 (Pubitemid 41191701)
9. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992;16: 276-282
10. 9- tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction [Epub ahead of print 2009 Oct 5].
11. Skopp G, Potsch L. Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. J Anal Toxicol 2008;32:160-164 (Pubitemid 351362750)
12. Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, Davis KH. Pharmacology of orally administered delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 1973;14:48-55.
13. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-1804
14. Lemberger L, Crabtree RE, Rowe HM. 11- Hydroxy-delta-9- tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marijuana in man. Science (Wash DC) 1972;177:62-64
15. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28: 409-416 (Pubitemid 10007024)
16. Wall ME, Perez-Reyes M. The metabolism of delta- 9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 1981;21:178S-89S.
17. Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 2006;28:545-551
18. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, et al. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 1995;19: 292-298
19. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA. Simultaneous GC-EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxydelta9- tetrahydrocannabinol, and 11-nor-9- carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 2007;31:477-485
20. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA. Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 1995;19:285-291
21. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16:228-235
22. Gustafson RA, Moolchan ET, Barnes A, Levine B, Huestis MA. Validated method for the simultaneous determination of delta-9- tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatographymass spectrometry with positive chemical ionization. J Chromatogr B 2003;798:145-154 (Pubitemid 37421291)
23. Wall ME, Taylor HL. Conjugation of acidic metabolites of delta-8 and delta-9-THC in man. In: Harvey DJ, Paton SW, Nahas GG, eds. Marihuana 84 Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Ltd, 1984:69-76.
24. Law B, Mason PA, Moffat AC, Gleadle RI, King LJ. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 1984;36:289-294 (Pubitemid 14101357)
25. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981;21:143S-52S.
26. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 1999;141:385-394 (Pubitemid 29190007)
27. Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980;215:35-44.
28. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA. Simultaneous quantification of delta- 9-tetrahydrocannabinol (THC), 11-hydroxy-delta- 9-tetrahydrocannabinol (11-OH-THC), and 11- nor-delta-9-tetrahydrocannabinol-9- carboxylic acid (THCCOOH) in human plasma using twodimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 2007;1163:318-327
29. ElSohly M, Feng S. Delta-9-THC metabolites in meconium: identification of 11-OH-delta-9-THC, 8 beta,11-diOH-delta-9-THC, and 11-nor-delta-9- THC-9-COOH as major metabolites of delta-9- THC. J Anal Toxicol 1998;22:329-335
30. Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9- tetrahydrocannabinol in cancer patients. Cancer Treat Rep 1984;68:1427-1431 (Pubitemid 15187570)
31. Lemberger L, Tamarkin NR, Axelrod J. Delta-9- tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science (Wash DC) 1971;173:72-74
32. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L. Pharmacokinetics and metabolism of delta-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986;38:21-43. (Pubitemid 16077324)
33. Harvey DJ, Paton WDM. Metabolism of the cannabinoids. Rev Biochem Toxicol 1986;6:221-264
34. Glaz-Sandberg A, Dietz L, Nguyen H, Oberwittler H, Aderjan R, Mikus G. Pharmacokinetics of 11-nor-9- carboxy-delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther 2007;82:63-69
35. Sallustio BC, Sabordo L, Evans AM, Nation RL. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab 2000;1: 163-180
36. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP- glucuronosyltransferase 1A locus in human colon: identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998;273:8719-8726
37. Yamanaka H, Nakajima M, Katoh M, Yokoi T. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 2007;35:1642-1648 (Pubitemid 47296059)
38. Skopp G, Potsch L, Mauden M, Richter B. Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-delta- 9-carboxy tetrahydrocannabinol glucuronide. Forensic Sci Int 2002;126:17-23. (Pubitemid 34292522)
39. Skopp G, Potsch L. Stability of 11-nor-delta(9)- carboxy- tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatographytandem mass spectrometry. Clin Chem 2002;48: 301-306